Introduction
Quinazolinone derivatives represent one of the most active classes of compounds possessing a wide spectrum of biological activity. ey are widely used in pharmaceuticals and agrochemicals. Several reports have been published on the biological activities of quinazolinone derivatives, including their anti-in�ammatory [1] [2] [3] [4] [5] [6] [7] , antimalarial [8, 9] , antimicrobial, anti-fungal, antibacterial [10] [11] [12] [13] [14] [15] [16] , anticonvulsant [17] [18] [19] [20] , and antitumor [21, 22] activities. Moreover, large number of quinazolinone derivatives having substitution at 2 and 3 position by different heterocyclic moieties increases antiin�ammatory potential of quinazolinone derivatives. Similarly, various azetidinones [23] [24] [25] and thiazolidinones [26, 27] have been reported to possess potent anti-in�ammatory activity. Looking to the medicinal importance of 4(3H)-quinazolinone, 4-thiazolidinone, and azetidinones, we report here the synthesis of a new class of heterocyclic molecules in which all of these moieties are present and try to develop potential bioactive molecules. e structures of the compounds synthesized were assigned on the basis of elemental analysis, IR, 1 H NMR, and Mass spectral data. ese compounds were evaluated for their anti-in�ammatory and analgesic activities.
Materials and Methods

2.1.
Chemistry. e synthetic routes of compounds are outlined in Scheme 1. As shown in Scheme 1, compounds 2-methylsubstitued-4H-3,1-benzoxazin-4-ones (1, 2) were synthesized by the known procedure of Bogert [28] . Substituted anthranilic acid reacted with acetic anhydride to give 2-methylsubstituted-4H-3,1-benzoxazin-4-ones (1, 2) , which further reacted with 2-amino phenyl amine in acetic acid to yield 3-(2 ′ -aminophenyl)-2-methyl-6-substituted quinazolin-4-ones (3, 4) . Compounds (3, 4) when treated with different substituted aromatic aldehydes formed various substituted arylidene derivatives (5) (6) (7) (8) (9) (10) . ese arylidene derivatives on treatment with chloroacetylchloride in presence of triethylamine yielded 3-[2 (11) (12) (13) (14) (15) (16) . On the other hand, these arylidene derivatives on reaction with thioglycolic acid and anhydrous ZnCl 2 furnished 3-
′′ -thiazolidin-3 ′′ -yl)phenyl]-2-methyl-6-substitutedquinazolin-4-ones. (17) (18) (19) (20) (21) (22) . e structures of the compounds synthesized were assigned 
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Biological Activity.
e experiments were performed with albino rats of the Charles-foster stain of either sex, excluding pregnant females, of 70-95 d. weighting 100-150 g. Food (chaw pallet) and water were given to the animals ad libitum. All the compounds were dissolved in propylene glycol. Phenylbutazone was used as reference drug.
Anti��n�ammatory Activity against �arrageenan��nd�ced
Rat's Paw Oedema. is study was done with the procedure of Winter et al. [29] . e rats were divided into three groups (control, treated, and standard drug) of six animals each. A freshly prepared suspension of carrageenan (1% in 0.9% saline) 0.05 mn was injected under the planter aponeurosis of the right hind paw of each rat. Test compounds and standard drug were administered orally to the animals of drug-treated groups and the standard drug group, respectively, 1 h before the carrageenan injection. e paw volume of each rat was measured before 1 and aer 3 h of carrageenan treatment with the help of a plethysmometer. e percent anti-in�ammatory activity was calculated according to the formula given below
Percentage of inhibition of oedema = 1 − × 100,
where and are the mean increase in paw volume of rats of the treated and the control group, respectively. Results were statistically analyzed.
Analgesic Activity. is activity was assessed following the method of Berkowitz et al. [30] . is method is based on the property of the test compound to antagonize the phenyl quinone-induced pain syndrome in mice. Groups of �ve mice were injected intraperitoneally with 0.25 mL of a 0.02% solution of phenylquinone in ethanol (5%) 1 h aer of oral administration of the test compound. e number of writhes induced in each mouse was counted for 5 min (between 5 and 10 min) aer injection of an irritant. e analgesic effect was expressed as percent protection in comparison to control.
% protection = 1 − mean number of writhes in mice of test groups mean number of writhes in mice of control group
Experimental.
Melting points were determined in one-end-open capillary tube on omas Hoover melting apparatus and are uncorrected. e purities of compounds were checked by thin layer chromatography (TLC) using silica gel-G coated plats. e spots were developed in an iodine chamber and visualized under ultraviolet (UV) lamp. Infrared (IR) absorption spectra were recorded on PerkinElmer RX-1 FTIR spectrometer using potassium bromide (KBr) pellet, and wave numbers were given in cm −1 . e 1 H NMR spectra were recorded in CDCl 3 on a Bruker Avance II 400 NMR spectrometer (400 MHz). e 13 C NMR spectra were recorded in CDCl 3 on a Bruker Avance II 400 NMR spectrometer operating at 100 MHz. e chemical shis are reported in part per million ( ppm) using trimethylsilane (TMS) as an internal standard. Elemental analysis (C, H, N) was performed on Perkin-Elmer 2400 analyzer, and values were either in ±0.4% of the calculated.
3-( 2 ′ -Aminophenyl)-2-Methyl-Quinazolin-4-one ( 3).
A mixture of 2-methyl-4H-3,1-benzoxazin-4-one (1) + at m/z 251. e following compound was prepared using a similar procedure described for compound 3. + at m/z 330.
3-[ 2 ′ -(Benzylideneamino)Phenyl]-2-Methyl-Quinazolin-4-one ( 5).
A solution of compound 3 (0.01 moles) in ethanol (55 mL) was re�uxed with benzaldehyde (0.01 moles) separately in the presence of glacial acetic acid (2.5 mL) for 11 hr. e reaction mixture was concentrated, cooled, and then poured into ice water. e separated solid was �ltered and recrystallized from methanol to give compound 29 (63%) m.p. + at m/z. 339. e following compounds were prepared using a similar procedure described for compound 5. + at m/z. 448 (11) . To a solution of compound 5 (0.01 mole) and triethylamine (0.5 mL) in ethanol (55 mL) was added in monochloroacetylchloride (0.014 mole) at 50 ∘ C. e reaction mixture was stirred for 45 min. at room temperature and re�uxed for 8 hr. e reaction mixture was �ltered to removed triethylamine hydrogen chloride and the resultant solution was poured onto crushed ice with constant stirring. e solid thus obtained was recrystallized from acetone to give desired compound 11 (60%) m.p. + at m/z 415.5. e following compounds were prepared using a similar procedure described for compound 11. + at m/z 445.5. (14) . (58%) + at m/z 494.5. + at m/z 529. + at m/z 524.5. (17) . A mixture of compound 5(0.01 moles), thioglycolic acid (0.012 moles) in absolute dioxane (75 mL) and in the presence of anhydrous ZnCl 2 was re�uxed for 18 hr. �e solvent was removed under reduced pressure. �e solid thus obtained was �ltered and washed with water. �e product �nally obtained was dried and recrystallized from ethanol to yield compound 17 (55%) m.p. + at m/z 413. + at m/z 526.5. (22 4%) than compounds 5, 6, 7, 8 , and 10. Cyclizations of these compounds into azetidinones and thiazolidinones have shown better anti-in�ammatory activity than corresponding arylidene derivatives. Azetidinones (11) (12) (13) (14) (15) (16) and thiazolidinones (17) (18) (19) (20) (21) (22) have shown the antiin�ammatory activity from (24.6-27.3%) and (22.9-32.5%) respectively. In azetidinones, compound 15 showed better anti-in�ammatory activity at the dose of 50 mg/kg p.o. than compounds 11, 12, 13, 14, and 16. Compound 11 exhibited lower percentage inhibition of oedema (24.6%) among azetidinones. iazolidinones (17) (18) (19) (20) (21) (22) generally showed better anti-in�ammatory then corresponding azetidinones (11) (12) (13) (14) (15) (16) (21) showed better anti-in�ammatory activity (32.5%).
3-[2
′ -(3 ′′ -Chloro-2 ′′ -Oxo-4 ′′ -(p-Chlorophenyl)Azetidin- 1 ′′ -yl)-Phenyl]-2-
′ -(3 ′′ -Chloro-2 ′′ -Oxo-4 ′′ -Phenylazetidin-1 ′′ -yl)-Phenyl]- 2-Methyl-6-Bromo-Quinazolin-4-one
′ -(3 ′′ -Chloro-2 ′′ -Oxo-4 ′′ -(p-Chlorophenyl)Azetidin-1 ′′ - yl)-Phenyl]-2-Methyl-6-Bromo Quinazolin
′ -(3 ′′ -Chloro-2 ′′ -Oxo-4 ′′ -(P-Methoxyphenyl)Azetidin- 1 ′′ -yl)-Phenyl]-2-Methyl3-[2 ′ -(2 ′′ -Phenyl-4 ′′ -Oxo-1 ′′ , 3 ′′ -iazolidin-3 ′′ -yl)Phenyl]-2- Methyl-6-Quinazolin-4-one3-[2 ′ -(2 ′′ -(p-Chlorophenyl)-4 ′′ -Oxo-1 ′′ , 3 ′′ -iazolidin- 3 ′′ -Yl)Phenyl]-2-Methyl-Quinazolin-4-one. (183-[2 ′ -(2 ′′ -(p-Methoxyphenyl)-4 ′′ -Oxo-1 ′′ ,3 ′′ -iazolidin-3 ′′ - yl)Phenyl]-2-Methyl-6-Bromo Quinazolin-4-one
Analgesic Activity.
Compounds (5-10) have shown moderate analgesic activity (11.6-19.3%). e compound 9 showed good analgesic activity (19.3%) then compounds 5, 6, 7, 8, and 10. e formation of azetidinones (11) (12) (13) (14) (15) (16) and thiazolidinones (17-22) from compounds (5-10) showed better analgesic activity than corresponding arylidene derivatives. Among these, compound 21 showed the better analgesic activity (29.6%) than other tested compounds. e results of the biological study are depicted in Table 1 .
Conclusion
It may be concluded that the compounds having 4-chlorophenyl group of quinazolinone moiety showed better anti-in�ammatory activity than phenyl moiety. Azetidinone and thiazolidinone derivatives were found active than corresponding schiff base derivatives. Further, thiazolidinones showed better anti-in�ammatory and analgesics activities in comparison to their corresponding azetidinones. Among all the tested compounds, compound 21 showed better antiin�ammatory (32.5%) and analgesics (29.6%) activities than other compounds of series.
